• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: AML treatment market to witness modest growth by 2020

Report: AML treatment market to witness modest growth by 2020

November 26, 2014
CenterWatch Staff

The value of the global acute myeloid leukemia (AML) therapeutics market will increase moderately from $632.6 million in 2013 to $878.6 million by 2020, representing a Compound Annual Growth Rate (CAGR) of 4.8%, according to New York-based business intelligence provider GBI Research.

The company’s latest report states that this growth, which will occur across eight major markets (the U.S., U.K., Canada, Germany, France, Italy, Spain and Japan), is attributable to rising AML prevalence and the anticipated launches of five premium-priced drugs into a market dominated by generics.

Promising novel treatments, CPX-351, midostaurin, quizartinib, StemEx and treosulfan, have demonstrated encouraging efficacy and safety benefits in small patient cohorts in early clinical trials. These drugs are expected to show similar positive results in later studies, resulting in their approval during the forecast period, following which they are expected to outcompete inferior drugs and increase treatment rates.

Katie Noon, analyst for GBI Research, said, “The current developmental pipeline for AML has a strong number of drug candidates in both the late and early stages, especially for an orphan indication.”

“While AML treatment is dominated by generic chemotherapeutic agents, which have been the treatment of choice for the past four decades, the pipeline dynamics now suggest a strong focus on targeted therapies,” said Noon. “These are predominately small molecule inhibitors of serine threonine proteins kinases, immunological agents against tumor-associated antigens/genes and antagonists against cell-surface receptors.”

Despite the active pipeline, GBI Research found increasing stem cell transplant rates, combined with a lack of standardized treatment and high disease heterogeneity, could decrease AML prevalence, therefore hindering the positive effects of new drug approvals and AML drug market expansion by 2020.

Noon said, “A rise in stem cell transplants will allow for long-term remissions and higher recovery rates, lowering both AML prevalence and the demand for pharmacological therapeutics.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing